BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 31614935)

  • 21. Treatment directed to signalling molecules in patients with advanced differentiated thyroid cancer.
    Sáez JM
    Anticancer Agents Med Chem; 2013 Mar; 13(3):483-95. PubMed ID: 22583421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TBX1 Functions as a Tumor Suppressor in Thyroid Cancer Through Inhibiting the Activities of the PI3K/AKT and MAPK/ERK Pathways.
    Wang N; Li Y; Wei J; Pu J; Liu R; Yang Q; Guan H; Shi B; Hou P; Ji M
    Thyroid; 2019 Mar; 29(3):378-394. PubMed ID: 30543152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HABP2 Gene Mutations Do Not Cause Familial or Sporadic Non-Medullary Thyroid Cancer in a Highly Inbred Middle Eastern Population.
    Alzahrani AS; Murugan AK; Qasem E; Al-Hindi H
    Thyroid; 2016 May; 26(5):667-71. PubMed ID: 26906432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leptin enhances migration of human papillary thyroid cancer cells through the PI3K/AKT and MEK/ERK signaling pathways.
    Cheng SP; Yin PH; Hsu YC; Chang YC; Huang SY; Lee JJ; Chi CW
    Oncol Rep; 2011 Nov; 26(5):1265-71. PubMed ID: 21750869
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of endothelial cell proliferation by Notch1 signaling is mediated by repressing MAPK and PI3K/Akt pathways and requires MAML1.
    Liu ZJ; Xiao M; Balint K; Soma A; Pinnix CC; Capobianco AJ; Velazquez OC; Herlyn M
    FASEB J; 2006 May; 20(7):1009-11. PubMed ID: 16571776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of a novel germline FOXE1 variant in patients with familial non-medullary thyroid carcinoma (FNMTC).
    Pereira JS; da Silva JG; Tomaz RA; Pinto AE; Bugalho MJ; Leite V; Cavaco BM
    Endocrine; 2015 May; 49(1):204-14. PubMed ID: 25381600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metastatic function of BMP-2 in gastric cancer cells: the role of PI3K/AKT, MAPK, the NF-κB pathway, and MMP-9 expression.
    Kang MH; Oh SC; Lee HJ; Kang HN; Kim JL; Kim JS; Yoo YA
    Exp Cell Res; 2011 Jul; 317(12):1746-62. PubMed ID: 21570392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nucleus pulposus cells upregulate PI3K/Akt and MEK/ERK signaling pathways under hypoxic conditions and resist apoptosis induced by serum withdrawal.
    Risbud MV; Fertala J; Vresilovic EJ; Albert TJ; Shapiro IM
    Spine (Phila Pa 1976); 2005 Apr; 30(8):882-9. PubMed ID: 15834331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.
    Shimizu T; Tolcher AW; Papadopoulos KP; Beeram M; Rasco DW; Smith LS; Gunn S; Smetzer L; Mays TA; Kaiser B; Wick MJ; Alvarez C; Cavazos A; Mangold GL; Patnaik A
    Clin Cancer Res; 2012 Apr; 18(8):2316-25. PubMed ID: 22261800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Both mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinases (ERK) 1/2 and phosphatidylinositide-3-OH kinase (PI3K)/Akt pathways regulate activation of E-twenty-six (ETS)-like transcription factor 1 (Elk-1) in U138 glioblastoma cells.
    Mut M; Lule S; Demir O; Kurnaz IA; Vural I
    Int J Biochem Cell Biol; 2012 Feb; 44(2):302-10. PubMed ID: 22085529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Coactivation of the PI3K/Akt and ERK signaling pathways in PCB153-induced NF-κB activation and caspase inhibition.
    Liu C; Yang J; Fu W; Qi S; Wang C; Quan C; Yang K
    Toxicol Appl Pharmacol; 2014 Jun; 277(3):270-8. PubMed ID: 24726520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fak/Src signaling in human intestinal epithelial cell survival and anoikis: differentiation state-specific uncoupling with the PI3-K/Akt-1 and MEK/Erk pathways.
    Bouchard V; Demers MJ; Thibodeau S; Laquerre V; Fujita N; Tsuruo T; Beaulieu JF; Gauthier R; Vézina A; Villeneuve L; Vachon PH
    J Cell Physiol; 2007 Sep; 212(3):717-28. PubMed ID: 17443665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.
    McCubrey JA; Steelman LS; Kempf CR; Chappell WH; Abrams SL; Stivala F; Malaponte G; Nicoletti F; Libra M; Bäsecke J; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Cocco L; Martelli AM
    J Cell Physiol; 2011 Nov; 226(11):2762-81. PubMed ID: 21302297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy.
    Martelli AM; Tabellini G; Ricci F; Evangelisti C; Chiarini F; Bortul R; McCubrey JA; Manzoli FA
    Adv Biol Regul; 2012 Jan; 52(1):214-27. PubMed ID: 21983557
    [No Abstract]   [Full Text] [Related]  

  • 35. Immunostimulatory Effects of Chitooligosaccharides on RAW 264.7 Mouse Macrophages via Regulation of the MAPK and PI3K/Akt Signaling Pathways.
    Yang Y; Xing R; Liu S; Qin Y; Li K; Yu H; Li P
    Mar Drugs; 2019 Jan; 17(1):. PubMed ID: 30626153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel germline RET mutation segregating with papillary thyroid carcinomas.
    Rey JM; Brouillet JP; Fonteneau-Allaire J; Boneu A; Bastié D; Maudelonde T; Pujol P
    Genes Chromosomes Cancer; 2001 Dec; 32(4):390-1. PubMed ID: 11746981
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways.
    Kandil E; Tsumagari K; Ma J; Abd Elmageed ZY; Li X; Slakey D; Mondal D; Abdel-Mageed AB
    J Surg Res; 2013 Oct; 184(2):898-906. PubMed ID: 23602735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low mutational burden of eight genes involved in the MAPK/ERK, PI3K/AKT, and GNAQ/11 pathways in female genital tract primary melanomas.
    Pappa KI; Vlachos GD; Roubelakis M; Vlachos DE; Kalafati TG; Loutradis D; Anagnou NP
    Biomed Res Int; 2015; 2015():303791. PubMed ID: 25695059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extracellular Signal-Regulated Kinases 1 and 2 Phosphorylate Gab2 To Promote a Negative-Feedback Loop That Attenuates Phosphoinositide 3-Kinase/Akt Signaling.
    Zhang X; Lavoie G; Méant A; Aubert L; Cargnello M; Haman A; Hoang T; Roux PP
    Mol Cell Biol; 2017 Apr; 37(7):. PubMed ID: 28096188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SOSTDC1 inhibits follicular thyroid cancer cell proliferation, migration, and EMT via suppressing PI3K/Akt and MAPK/Erk signaling pathways.
    Zhou Q; Chen J; Feng J; Xu Y; Zheng W; Wang J
    Mol Cell Biochem; 2017 Nov; 435(1-2):87-95. PubMed ID: 28551845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.